Aerovance, Inc.: Series C $60M

Aerovance (Berkeley, CA) a biopharmaceutical company focused on the development asthma, cystic fibrosis and chronic obstructive pulmonary disease has closed a $60M Series C. Participants in the round included Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & CO.

Orqis Medical Corp.: Series D $37.4M

Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.

Amira Pharmaceuticals, Inc.: Series B $25M

Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNFα pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.

Microbia, Inc.: Series F $50M

Microbia (Cambridge, MA) rational drug designer focused on GI and cardiovascular therapeutics raised a $50M series F round. The financing was led by Ridgeback Capital and joined by Morgan Stanley Investment Management.

CORRECTION: Symphony Medical, Inc.

Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised $5M, bringing the aggregate investment in all rounds into Symphony Medical to $17 million. The only participants in the round were Domain Associates, Johnson & Johnson Development Corp., Morgenthaler Ventures and Triathlon Medical Ventures.

Symphony Medical, Inc.: Series B $11.2M

Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised another $11.2M in Series B funding. Participants include Domain Associates, Johnson & Johnson Development Corp., Morgenthaler Ventures, Triathlon Medical Ventures and Guidant Compass Group.